Kornimate/medical-research-clean huggingface dataset:
efficacy of adjunctive low-level light therapy to intense pulsed light for meibomian gland dysfunction

Conditions: MGD-Meibomian Gland Dysfunction

Summary: the goal of this clinical trial is to compare the effectiveness of adjunctive low-level light therapy (lllt) to intense pulsed light (ipl) versus intense pulsed light (ipl) alone for the treatment of meibomian gland dysfunction (mgd). the main question it aims to answer is does the adjunctive of low-level light therapy (lllt) to intense pulsed light (ipl) provide more beneficial treatment effects than intense pulsed light (ipl) alone in treating meibomian gland dysfunction (mgd) patients? participants will be randomized into 2 groups: adjunctive low-level light therapy (lllt) to intense pulsed light (ipl) group (alllt +ipl) and ipl alone group.

in both the ipl group and the alllt+ipl group, the doctor will administer ipl therapy to each participant and apply the light modulation® special facial mask to their faces. the assistant nurse will activate the light power, ensuring that the doctor remains blind to treatment allocation. participants in both groups will receive a conventional treatment for mgd including warm compression and lid hygiene. moreover, all participants will be advised to use preservative-free artificial tears 4 times daily throughout the study.

Eligibility criteria:
inclusion criteria: * mgd severity level 2 and above according to the international workshop on mgd * fitzpatrick skin type of 1-4 according to sun sensitivity characteristics and appearance of the skin color exclusion criteria: * history of previous ocular trauma or surgery within the past six months * contact lens-wearing patients * patients with skin-pigmented lesions in the treatment area * pregnancy or breastfeeding patients * patients with any uncontrolled ocular or systemic diseases
photographic posture analysis in children with cerebral palsy

Conditions: Posture Disorders in Children; Cerebral Palsy

Summary: cerebral palsy (cp), which is the largest group of patients among pediatric neuromuscular diseases, is a non-progressive permanent disorder that affects muscle control, movement, posture and balance. the purpose of this study; to evaluate the reliability of photographic posture analysis in the sitting position in children with cp and to examine the relationship between the results of photographic posture analysis with the motor performances and trunk control of children with cp.children with cp were included in the study according to the following criteria; aged 5-12 years, diagnosed as spastic diplegia or hemiplegia , having a level of "i, ii, iii" according to gmfcs. postural evaluation was done using the photographic method. trunk control was evaluated with trunk control measurement scale,motor performance of children was evaluated with gross motor function measure-88. icc values for photographic posture analysis was found to be highly reliable.

sitting position is of great importance in the development of upper extremity functions, orthogonal functional skills, personal care, cognitive, perceptual and social skills in children with cerebral palsy and these kids spend most of their time in a sitting position.there are goniometer, inclinometer, flexicurve, spinal mouse, and modified head posture spinal curvature ınstrument tools for posture analysis in the sitting position.however, none of these measurement tools have been validated for validity and reliability studies of head and trunk posture measurement in the sitting position in children with cp. methods such as magnetic resonance (mr) and x-ray used in posture evaluation provide clear images of reference points and are the gold standard in the literature. however, they are not preferred much because they are expensive and contain radiation.photographic posture analysis can be considered as a measurement method such as posture analysis methods using the gravity line. it is a digital, more objective measurement method that measures linear distances and angles using anatomical reference points using specially designed software. clinical use of photographic posture analysis is recommended in the literature, as it is an accurate and objective method, preventing radiation exposure.the purpose of this study; to evaluate the reliability of photographic posture analysis in the sitting position in children with cp and to examine the relationship between the results of photographic posture analysis with the motor performances and trunk control of children with cp.

Eligibility criteria:
inclusion criteria: * aged 5-12 years, * diagnosed as spastic diplegia or hemiplegia, * having a level of "i, ii, iii" according to gmfcs exclusion criteria: * children who could not cooperate, * have undergone spinal surgery, had botulinum toxin (bont) and surgical treatment in the last 6 months * had another neurodevelopmental or congenital disease other than cp

Keywords: trunk posture analysis cerebral palsy performance
study of oral fampridine-sr in multiple sclerosis

Conditions: Multiple Sclerosis

Summary: to assess the safety and efficacy of 10 milligram (mg) twice a day (b.i.d.) fampridine-sr in patients diagnosed with multiple sclerosis (ms), in a double-blind, placebo-controlled, parallel group study.

multiple sclerosis (ms) is a disorder of the body's immune system that affects the central nervous system (cns). normally, nerve fibers carry electrical impulses through the spinal cord, providing communication between the brain and the arms and legs. in people with ms, the fatty sheath that surrounds and insulates the nerve fibers (called "myelin") deteriorates, causing nerve impulses to be slowed or stopped. as a result, patients with ms may experience periods of muscle weakness and other symptoms such as numbness, loss of vision, loss of coordination, paralysis, spasticity, mental and physical fatigue and a decrease in the ability to think and/or remember. these periods of illness may come (exacerbations) and go (remissions). fampridine-sr is an experimental drug that has been reported to possibly improve muscle strength and walking ability for some people with ms. this study will evaluate the effects and possible risks of taking fampridine-sr in subjects with ms.

Eligibility criteria:
inclusion criteria: * have a confirmed diagnosis of multiple sclerosis * are able to walk with or without an assistive device exclusion criteria: * pregnancy, breastfeeding or females of childbearing potential not using adequate birth control * participating in other investigational drug trials * a medical history or clinical findings that preclude entry into the study * a medication history that precludes entry into the study * previously treated with 4-aminopyridine (4-ap)

Keywords: walking ability
implementation of ivs3 for upper limb motor recovery

Conditions: Neglect, Hemispatial; Stroke, Cardiovascular; Mirror Movement; Motor Activity

Summary: this study measures participant satisfaction and upper extremity function in outpatients with chronic stroke when exposed to the ivs3 device. investigators hypothesize that treatment with the ivs3 device will be feasible and tolerable for use in the outpatient setting.

this study will investigate the implementation of the intensive visual stimulation three (ivs3) device in the outpatient rehabilitation setting. this is a phase i/ii open label study that will assess participant satisfaction and upper extremity function in outpatients with chronic stroke (10 with hemi spatial neglect and 15 without), when exposed to ivs3 for 30 minutes and conventional treatment for 15 minutes, across 12 sessions in 4-6 weeks at weill cornell medicine outpatient rehabilitation (single site).

Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old 2. english speaking 3. history of ischemic or hemorrhagic stroke ≥ 6 months prior to study enrolment 4. fma-ue: 20 \< x \< 50 (moderate impairments) 5. with or without hemi spatial neglect exclusion criteria: 1. spasticity or increased tone with mas ≥3 in the upper extremity 2. unable to communicate effectively or provide informed consent 3. significant visual impairments 4. concurrent occupational therapy being received outside of the study 5. pregnant or incarcerated individuals
the reta-model: rehabilitation trail for workers on long-term sick leave in the healthcare sector

Conditions: Burnout

Summary: the reta-model is a rehabilitation model for return to work after long-term sickness absence (ltsa) due to stress or burnout. the reta-model will be validated in this trial among nurses and physicians currently in ltsa. the reta-model includes a three-week treatment with exercise, individual and collegial talks with psychology and lecturing. the control group will receive conventional rehabilitation from regular care.

the reta-model is a rehabilitation model for return to work after long-term sickness absence (ltsa) due to stress or burnout. the reta-model will be validated in this trial among nurses and physicians currently in ltsa. the reta-model includes a three-week treatment with exercise, individual and collegial talks with psychology and lecturing. the control group will receive conventional rehabilitation from regular care.

Eligibility criteria:
inclusion criteria: * currently on sick leave for burnout * employed in the swedish healthcare services as a nurse or as a physician exclusion criteria: -

Keywords: healthcare burnout stress return to work intervention
safety of amiodarone and ranolazine together in patients with angina

Conditions: Chronic Stable Angina; Coronary Artery Disease; Atrial Fibrillation; Ventricular Tachycardia

Summary: ranolazine is an effective and remarkably safe agent for the treatment of patients with chronic stable angina, but its inhibition of voltage gated potassium channels and electrocardiogram (ekg) corrected qt (qtc) prolongation properties have lead many to question its safety when combined with antiarrhythmic drugs. the investigators have proposed a study to determine the safety of ranolazine in patients with chronic stable angina who also take amiodarone. and are conducting a prospective single-center randomized single-blinded placebo controlled trial to run out of our large cardiology practice setting at cardiovascular consultants of nevada. the hypothesis is that there will be no difference in the ventricular arrhythmia burden. the primary outcome will be the measurement of ventricular arrhythmia episodes on serial holter monitor and other serially acquired recordings (such as electrocardiogram, pacemaker or implantable defibrillator (icd) data, and stress test data) over a three month trial period.


Eligibility criteria:
inclusion criteria: * ischemic cardiac disease * chronic anginal symptoms * on amiodarone therapy for other cardiac conditions exclusion criteria: * pregnant * non-english speaking * unstable angina * baseline electrocardiogram (ekg) corrected qt (qtc)\>490ms * severe thyroid dysfunction * heart block without a pacer system * liver disease

Keywords: amiodarone ranolazine safety arrhythmia
effect of spinal ketorolac on mechanical hypersensitivity after a total hip replacement

Conditions: Hip Arthroplasty

Summary: chronic pain in patients following total hip replacement seems to be a significant problem. previous research has shown that more effective pain management in the early postoperative period may decrease the incidence of the development of chronic pain states. this study will evaluate whether ketorolac (a non steroidal anti-inflammatory drug) given into the spinal fluid before surgery will reduce the area of sensitivity (or pain to light touch) following surgery. patients will be monitored during their postoperative hospital stay and then contacted by telephone at 8 weeks and 6 months after surgery and questioned about any pain they are having at their surgical site. patients that are still experiencing pain at 6 months will be asked to return to the medical center for the study staff to assess their pain or sensitivity at the surgical site.

surgery results in hypersensitivity to mechanical stimuli surrounding the wound and in a subset of patients, also results in chronic pain. the purpose of the study is to test whether intrathecal ketorolac, by selectively and effectively blocking cyclooxygenase in the spinal cord, will reduce hypersensitivity surrounding the surgical wound in patients with high risk for developing chronic pain after surgery. we have chosen to study patients having total hip arthroplasty (tha) because chronic pain seems to be a significant problem after surgery. we will sample cerebrospinal fluid (csf) prior to injection of the study medication for subsequent prostaglandin e2 (pge2) analysis in each patient. we will also assess each patient at 48 hours after their surgery for hypersensitivity at their surgical site.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) physical status i, ii, iii * \> age 18 * primary unilateral total hip arthroplasty under spinal anesthesia exclusion criteria: * known allergy to study medication * weight \> 300 pounds * obstructive sleep apnea * patients with severe renal (kidney) or hepatic (liver) disease, allergy to ketorolac, amino amide local anesthetic, or contraindications to spinal anesthesia * patients on dialysis for kidney failure or patients that are jaundice or have a diagnosis of liver failure * patients routinely taking narcotic pain medications for pain other than their primary hip pain * patients that are taking lyrica (pregabalin) or gabapentin (neurontin) for the treatment of seizures

Keywords: total hip arthroplasty total hip replacement pain, postoperative ketorolac patients undergoing unilateral total hip arthroplasty
food preparation effects on gut bacteria in patients on peritoneal dialysis

Conditions: End Stage Renal Disease (ESRD)

Summary: this is an intervention study of the effects of food preparation on the gut bacteria in patients with end stage renal disease on peritoneal dialysis. this is a dietary intervention consistent of consuming low amounts of advanced glycation end products (ages), the products of protein and sugar interaction during food processing and preparation using high direct heat.

gut microbes can influence numerous aspects of human biology. alterations in the function and composition of gut microbial flora (gut microbiota) have been linked to different diseases such as obesity, diabetes and inflammation. advanced glycation end products (ages) are formed via the maillard reaction, which consists of a complex network of non-enzymatic reactions involving the carbonyl groups of reducing sugars which react with the amino groups of proteins. ages are produced in vivo and being consumed. they have been implicated in increased risk of different diseases including atherosclerosis, cad and kidney diseases. in this study, the investigators are evaluating the effects of consuming a low age diet in participants on peritoneal dialysis on the gut bacteria and inflammation.

Eligibility criteria:
inclusion criteria: * age \> 18 years. * patients with esrd on pd. * patients are able to understand and give consent. * patients with estimated daily dietary age intake \> 12 age eq/day (12,000 kilounits/day) based on 3-day food records. exclusion criteria: * patient on antibiotics in the last three months. * liver cirrhosis, and heart failure with ef \< 30%. * the use of chemotherapy, immunosuppressive medications, probiotics, and steroid in the last month. * oral iron supplementation in the last month. * history of small or large intestine resection or small bowel obstruction

Keywords: end stage renal disease peritoneal dialysis (pd) advanced glycation end products gut microbiota inflammation
nuclear magnetic resonance spectroscopic analysis of urinary metabolome in sarcoidosis (rmn-sarcurines)

Conditions: Sarcoidosis

Summary: "sarcoidosis is a systemic granulomatous disease of unknown cause(s).determining disease activity is a major element in the treatment decision. 1h- nuclear magnetic resonance (nmr) spectroscopy allows the identification of biomarkers in different pathologies and in particular in a pilot study of saliva of patients with sarcoidosis. applications to sarcoidosis are still rare, having concerned only serum and saliva. in this context we hypothesize the existence of a difference in the metabolic products found in the urine of sarcoidosis patients with different degrees of activity and/or disease severity. we designed an analysis of urinary metabolomics in sarcoidosis patient using nmr spectroscopy with multivariate statistical analysis, followed by metabolite identification and pathway analysis. "

"sarcoidosis is a systemic granulomatous disease of unknown cause(s) with an almost constant lung involvement. clinical expression varies greatly in both evolution and severity. the activity of the disease is currently based on serum markers (elevation of angiotensin-converting enzyme) with poor sensitivity/specificity or on imaging techniques (18f-fdg pet-ct) which are more invasive and more expensive. determining disease activity is a major element in the treatment decision. the spectra of small molecules resulting from metabolism (metabolome/metabolomics) evaluated by spectrometry in different biological fluids (blood, saliva, urine) during different physiological or pathological conditions have been identified as promising biomarkers. 1h- nuclear magnetic resonance (nmr) spectrometry allows the identification of biomarkers in different pathologies and in particular in a pilot study of saliva of patients with sarcoidosis. applications to sarcoidosis are still rare having concerned only serum and saliva. the application of this method to the urinary metabolome has shown its effectiveness in other situations, for example in celiac disease. in this context we hypothesize the existence of a difference in the metabolic products found in the urine of sarcoidosis patients with different degrees of activity and/or disease severity. we designed an analysis of urinary metabolomics in sarcoidosis patient using nmr spectroscopy with multivariate statistical analysis, followed by metabolite identification and pathway analysis. "

Eligibility criteria:
inclusion criteria: * patients with a diagnosis of sarcoidosis according to ats / ers / wasog criteria. exclusion criteria: * treatment (corticosteroids, plaquenil, immunosuppressants) within the last 6 months * patients with diabetes. * patient with long-term or recent drug treatment (e.g. antibiotics) * patients with a urinary tract infection or urinary lithiasis at the time of collection. * renal failure

Keywords: sarcoidosis urinary nmr spectroscopy metabolomic
prevalence of metabolic syndrome in a maintenance hemodialysis population

Conditions: Metabolic Syndrome

Summary: the study is a survey to answer the specific question, "what is the prevalence of metabolic syndrome in maintenance hemodialysis patients?" metabolic syndrome is a cluster of conditions that increase an individual's risk for developing cardiovascular disease and diabetes.

risk factors for metabolic syndrome will be collected for each consented patient. they include elevated serum triglycerides, reduced hdl cholesterol, hypertension, elevated fasting blood sugar concentration and abdominal obesity. the investigator will measure waist circumference of each consented patient in a secure area according to standardized procedures. the other data is available from the patient's medical record.

Eligibility criteria:
inclusion criteria: * patients undergoing maintenance hemodialysis equal to or greater than 3 months * patient at lest 18 years of age * availability of all data in the medical record for classification of the metabolic syndrome, including serum triglycerides, serum hdl-cholesterol, systolic bp and diastolic bp, and serum glucose exclusion criteria: * patients unwilling or unable to give informed consent to participate * patients with a history of thyroid disease * patients unable to stand upright

Keywords: metabolic syndrome, esrd patient
effects of almonds on cardiovascular risk factors

Conditions: Cardiovascular Disease

Summary: the purpose of this research is to build the evidence base for approval of fda health claims related to almonds and cardiovascular disease. a randomized, 2-period, crossover controlled feeding study was designed to compare the effects of two blood cholesterol lowering diets that meet the american heart association recommendations. the nutrient profiles of the control diet (no almonds/day) and almond diet (1.5 oz. of almonds/day) are matched for protein, saturated fat, and cholesterol. the study population consists of two cohorts of 25 men and women with moderately elevated ldl-c. the investigators hypothesize that a cholesterol-lowering diet designed with almonds confers greater cardioprotective effects than a cholesterol-lowering diet without almonds on the basis of the ldl-c lowering response, effect on ldl particle size, abdominal adiposity and vascular health.


Eligibility criteria:
inclusion criteria: * bmi (20-35) * low density lipoprotein cholesterol males (128-194mg/dl) and females (121-190 mg/dl) exclusion criteria: * pregnant, planning to become pregnant, or lactating * smoking; cholesterol-lowering medication * glucose-lowering medication * over the counter cholesterol-lowering substances (e.g.: psyllium, fish oil, soy lecithin, phytoestrogen) * the following medical conditions: * heart disease * stroke * heart attack * blood pressure \>140/90 * diabetes * renal or kidney disease * rheumatoid arthritis * blood clotting disorder * liver disease or cirrhosis * compromised immune system * peripheral vascular disease or circulation problems \*\> 10% body weight loss in the past 6 months * vegetarian * nut allergies

Keywords: cardiovascular disease cholesterol low-density lipoprotein high-density lipoprotein triglycerides
effect of ginseol kg1 on blood pressure lowering

Conditions: Prehypertension; Hypertension, Stage I

Summary: in this study, we investigate the effects of ginseol kg1 (korea red ginseng extract) on blood pressure in prehypertensive or stage i hypertensive patients.

this is a multicenter, randomized, placebo-controlled, double-blind study. at the end of an initial 2-week washout period, patients fulfilling the inclusion criteria are assigned to three groups, i.e. control group (placebo), low dose ginseol kg1 group (100mg), or high dose ginseol kg1 (300mg) group. they will intake the study drug for 8 weeks. 24-h ambulatory bp monitoring (abpm) and pulse wave velocity are measured at the end of the washout period and after 8 weeks of active treatment. at each visit, seated sbp and dbp, heart rate, use of concomitant medication and spontaneously reported adverse events are recorded. compliance with medication (determined by counting returned tablets) is evaluated at each visit.

Eligibility criteria:
inclusion criteria: * age: adults over 20 years * prehypertension or stage 1 hypertension (systolic blood pressure 120\~159mmhg or diastolic blood pressure 80\~99mmhg) * subject who has not taken medications to treat hypertension within 15 days prior to first visit exclusion criteria: * subject who has been involved in other clinical trials within 30 days prior to first visit * subject who has following diseases within 2 years prior to screening: angina pectoris, myocardial infarction, heart failure, peripheral vascular disease, chronic liver failure, chronic renal failure, diabetes mellitus, hyperthyroidism, hypothyroidism, malignant tumor, mental disease * systolic blood pressure ≥ 160mmhg or diastolic blood pressure ≥ 100 mmhg during screening period * subject who has hepatic dysfunction(ast, alt ≥ 2.5 times higher than normal value) * subject who has renal dysfunction(creatinine ≥ 1.5 times higher than normal value) * subject who is pregnant or breast feeding * alcoholic * subject who has an allergy to the ingredients of study product

Keywords: blood pressure korea red ginseng ambulatory blood pressure pulse wave velocity